# Cervical Cancer

Cervical cancer care hinges on prevention through HPV-based screening, prompt risk-based evaluation of abnormal results, stage-appropriate local therapy, and biomarker-directed systemic treatment for persistent, recurrent, or metastatic disease.

**Clinical question:** How should clinicians integrate cervical cancer prevention, screening, diagnostic evaluation, and treatment selection across localized and recurrent or metastatic disease?

Updated: 2026-08-21T00:08:29.513487Z

## What matters in practice
- High-risk HPV is a necessary cause of virtually all cervical cancers; screening strategies must balance detection of CIN2+/CIN3+ against avoidable colposcopy and treatment harms. [1][14]
- Primary high-risk HPV testing is generally more sensitive and less specific than cytology alone; combined-test strategies alter this tradeoff according to the decision rule used. [14]
- For PD-L1-positive persistent, recurrent, or metastatic cervical cancer (CPS ≥1), pembrolizumab plus chemotherapy, with or without bevacizumab, improved median overall survival versus chemotherapy-based control in the FDA-reviewed trial. [8]
- Brachytherapy is an essential component of treatment for locally advanced cervical cancer and is associated with lower cervical cancer-specific and all-cause mortality in U.S. observational data. [18]

## Clinical priorities across the care continuum

Prioritize prevention, timely diagnostic resolution, and multidisciplinary treatment selection.

Cervical cancer prevention and early detection depend on validated high-risk HPV testing, cytology-based triage when indicated, and reliable completion of colposcopy and treatment pathways. High-risk HPV infection is considered necessary for virtually all cervical cancers; FDA guidance identifies 12 carcinogenic genotypes as core targets for high-risk HPV assays: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. [1]

Once invasive cancer is diagnosed, management is stage- and resectability-dependent and should be coordinated with gynecologic oncology and radiation oncology. Available evidence supports surgery or radiation-based treatment for localized disease, while concurrent chemoradiation is used for locally advanced disease; brachytherapy remains a critical component of definitive radiation treatment. [18][24]

For persistent, recurrent, or metastatic disease, treatment selection is driven by prior therapy, performance status, organ function, disease distribution, and tumor biomarkers—particularly PD-L1 expression for pembrolizumab eligibility in the FDA-approved first-line setting. [8]
- Do not equate an HPV-positive result with cancer; its principal near-term clinical role is risk stratification and triage. [1][14]
- Do not allow a negative HPV result to defer indicated colposcopy in a patient with high-grade cytology. [1]
- For potentially curative locally advanced disease, ensure referral to a center able to deliver brachytherapy. [18]

*High-value cervical cancer decisions across the care continuum. [1][8][18]*

| Clinical setting | Decision that changes care | Evidence-supported action |
| --- | --- | --- |
| Screening | Choice of screening test | High-risk HPV testing is more sensitive but less specific than cytology alone; use a validated programmatic strategy with defined triage. [14] |
| Abnormal screening result | Need for diagnostic evaluation | Interpret HPV, cytology, and genotype results in a risk-based pathway; high-grade cytology requires evaluation even with a negative HPV result. [1] |
| Locally advanced disease | Definitive local modality | Incorporate brachytherapy into definitive radiation treatment when indicated; omission is associated with worse survival in observational U.S. data. [18] |
| Persistent, recurrent, or metastatic disease | Systemic treatment eligibility | Obtain PD-L1 testing with an FDA-approved assay when considering pembrolizumab-containing first-line therapy; FDA indication requires CPS ≥1. [8] |

## Use validated HPV-based screening and risk-based triage

Test performance and downstream harms should determine the screening pathway.

The supplied evidence supports three broad screening modalities: cytology alone, high-risk HPV testing alone, and cotesting. In a network meta-analysis of 27 prospective studies involving 185,269 asymptomatic women, non-HPV16/18 high-risk HPV assays were generally more sensitive and less specific for CIN2+ than standalone cytology. [14]

Combining cytology and high-risk HPV testing increases or decreases sensitivity and specificity according to the rule used. An either-positive rule maximizes sensitivity at the expense of specificity, whereas requiring both tests to be positive increases specificity but lowers sensitivity. This tradeoff matters because false-positive screening tests lead to additional testing, colposcopy, biopsy, and potential overtreatment. [14]

FDA device guidance emphasizes that clinical validity is tied to the specific intended use, population, specimen type, collection medium, and assay cutoff. A negative result does not validate an assay outside its approved specimen and clinical-use setting. False-negative results can delay diagnosis, whereas false-positive results can lead to unnecessary colposcopy, biopsy, and potentially fertility-affecting treatment. [1]
- Use only assays and collection systems validated for the intended screening application. [1]
- Treat HPV16/18 genotype information as risk stratification, not as a substitute for the full screening-management pathway. [1][14]
- Recognize that test-performance comparisons from heterogeneous screening studies do not replace current U.S. risk-based management guidance for an individual patient. [14]

### Emerging self-collected and urine-based testing

First-void urine HPV and methylation testing is investigational for routine U.S. cervical screening based on the supplied literature. In a referral-enriched European study, urinary ASCL1/LHX8 methylation had validated CIN3+ sensitivity of 73.0% and specificity of 81.9%; urinary HPV testing was more sensitive but less specific. These data cannot establish a U.S. screening interval or replace approved cervical-sample pathways. [13]
- Do not extrapolate referral-population diagnostic accuracy to average-risk U.S. screening populations. [13]
- Longitudinal screening-cohort validation remains necessary before urine methylation triage can be considered program-ready. [13]

*Relative test-performance implications for CIN2+ screening in asymptomatic women. [14]*

| Strategy | Sensitivity implication | Specificity implication | Clinical consequence |
| --- | --- | --- | --- |
| High-risk HPV testing alone versus cytology alone | Generally higher. [14] | Generally lower. [14] | Finds more precancer but increases positive results requiring triage. [14] |
| HPV plus cytology, either-positive rule | Highest among compared combination approaches. [14] | Lowest among compared combination approaches. [14] | Minimizes missed disease at cost of more downstream procedures. [14] |
| HPV plus cytology, both-positive rule | Lower. [14] | Highest among compared combination approaches. [14] | Reduces false positives but risks more missed CIN2+. [14] |

## Prevent diagnostic delay after abnormal screening

The immediate objective is histologic clarification without avoidable verification bias.

Colposcopy with biopsy, when indicated, provides the clinical reference standard for assessment of cervical precancer and cancer in HPV device studies. FDA guidance recommends standardized biopsy methods, blinded assessment of investigational HPV results, and pathology reporting that distinguishes CIN2 from CIN3 because CIN3 is more likely to progress to cancer. [1]

For women with ASC-US cytology undergoing HPV triage, FDA guidance describes prospective evaluation in which all women proceed to colposcopy irrespective of HPV status, with colposcopy performed within 12 weeks of the screening specimen. This design avoids verification bias in test assessment; in practice, management should follow current risk-based U.S. guidance rather than the device-study protocol alone. [1]

A negative HPV result should not prevent colposcopy when cytology is more severe than ASC-US. FDA specifically notes that, in women aged 30 years or older with greater than ASC-US cytology, a negative HPV result should not prevent referral to colposcopy. [1]
- Document cytology category using Bethesda terminology and obtain histology when colposcopy is indicated. [1]
- When pathology uses two-tier LAST terminology, retain clinically meaningful distinction between lower-grade and high-grade lesions and clarify whether terminology refers to cytology or histology. [1]
- Escalate promptly for suspected invasive disease; the supplied sources do not provide a complete staging-workup algorithm.

*Diagnostic-process safeguards supported by FDA HPV device guidance. [1]*

| Potential failure | Why it matters | Safeguard |
| --- | --- | --- |
| HPV-directed verification only | Can overestimate sensitivity by verification bias. [1] | Use risk-appropriate colposcopy and histology evaluation independent of investigational HPV status in clinical studies. [1] |
| Delayed colposcopy after ASC-US study enrollment | Lesion regression can distort performance estimates. [1] | FDA device-study guidance specifies completion within 12 weeks. [1] |
| Negative HPV with high-grade cytology | May falsely reassure despite a high-risk cytologic signal. [1] | Proceed with indicated colposcopy; HPV negativity should not block referral for >ASC-US cytology. [1] |

## Preserve curative options in localized and locally advanced disease

Treatment planning requires gynecologic oncology and radiation oncology coordination.

The supplied sources support surgery and radiation as principal modalities for localized cervical cancer, with concurrent chemoradiation described as the treatment of choice for locally advanced tumors. [24] Selection between surgery and radiation depends on disease extent, anticipated need for adjuvant treatment, patient comorbidity, and fertility implications; detailed stage-specific operative criteria are not available in the supplied sources.

For stage IB2–IVA cervical cancer, brachytherapy utilization is independently associated with lower cervical cancer-specific mortality and all-cause mortality in U.S. observational analyses. The source characterizes brachytherapy as an essential component of treatment for locally advanced cervical cancer. [18]

The practical implication is referral early enough to avoid substituting external-beam dose escalation for an indicated brachytherapy boost. MRI-guided brachytherapy has been associated with an approximately 10% overall-survival benefit compared with historical cohorts in the evidence summarized by the SEER analysis, but that estimate is not from a randomized comparison. [18]
- Refer patients with locally advanced disease to radiation programs that can deliver intracavitary or hybrid intracavitary-interstitial brachytherapy. [18]
- Avoid treatment sequencing that produces prolonged delays in definitive radiation or brachytherapy; the supplied sources do not provide an exact acceptable overall treatment-time threshold.
- Discuss fertility, ovarian function, sexual health, bowel and bladder toxicity, and survivorship needs before treatment planning; detailed rates are not available in the supplied sources.

*Local-treatment principles supported by supplied evidence. [18][24]*

| Disease context | Core treatment principle | Decision risk if omitted |
| --- | --- | --- |
| Localized disease | Use surgery or radiation-based local therapy as appropriate to disease extent and patient factors. [24] | Inappropriate modality selection may compromise cure or expose the patient to combined-modality morbidity. [24] |
| Locally advanced disease | Use primary concurrent chemoradiation, incorporating brachytherapy. [18][24] | Omission of brachytherapy is associated with inferior survival in observational data. [18] |

## Select systemic therapy by biomarker and prior treatment exposure

PD-L1 status is actionable in first-line persistent, recurrent, or metastatic disease.

For persistent, recurrent, or metastatic cervical cancer with tumor PD-L1 CPS of at least 1, the FDA approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, as first-line treatment. In the FDA-reviewed trial population with CPS at least 1, median overall survival was not reached with pembrolizumab-based therapy versus 16.3 months with placebo-based therapy (hazard ratio 0.64); median progression-free survival was 10.4 versus 8.2 months (hazard ratio 0.62). [8]

Tisotumab vedotin-tftv received FDA accelerated approval for adults with recurrent or metastatic cervical cancer progressing on or after chemotherapy. In a single-arm study of 101 patients treated with 2 mg/kg intravenously every 3 weeks, confirmed objective response rate was 24% and median response duration was 8.3 months. Labeling included a boxed warning for ocular toxicity. [3]

Topotecan plus cisplatin remains FDA-labeled for stage IVB, recurrent, or persistent cervical carcinoma not amenable to curative surgery or radiation. The labeled regimen is topotecan 0.75 mg/m² IV over 30 minutes on days 1–3 plus cisplatin 50 mg/m² IV on day 1 every 21 days. In the cited comparative trial, median survival was 9.4 months with the combination versus 6.5 months with cisplatin alone. [4]
- Order PD-L1 testing with an FDA-approved test before selecting pembrolizumab-containing first-line treatment; the FDA indication specifies CPS ≥1. [8]
- For tisotumab vedotin, arrange baseline and ongoing ophthalmic monitoring consistent with current product labeling; the supplied FDA summary identifies ocular toxicity as a boxed warning but does not provide the monitoring protocol. [3]
- For topotecan-cisplatin, confirm baseline marrow reserve and renal eligibility. Topotecan labeling requires baseline neutrophils greater than 1,500/mm³ and platelets greater than 100,000/mm³; cervical-cancer combination treatment should be initiated only when serum creatinine is 1.5 mg/dL or less. [4]

### Toxicity tradeoffs that affect regimen selection

Topotecan-cisplatin has substantial hematologic toxicity. In the cervical-cancer comparative trial, all-grade anemia, leukopenia, neutropenia, and thrombocytopenia occurred in 94%, 91%, 89%, and 74% of patients receiving the combination, respectively; grade 4 neutropenia occurred in 48%. [4]

Tisotumab vedotin adverse effects commonly included decreased hemoglobin, fatigue, nausea, peripheral neuropathy, hemorrhage, conjunctival adverse reactions, dry eye, and laboratory cytopenias. [3] These risks should be weighed against prior toxicity, tumor-related bleeding risk, neuropathy, and capacity for ophthalmic surveillance.
- Do not administer topotecan with baseline neutrophils below 1,500/mm³. [4]
- Monitor peripheral blood counts frequently during topotecan therapy; defer subsequent courses until neutrophils exceed 1,000/mm³, platelets exceed 100,000/mm³, and hemoglobin is 9 g/dL or greater, with transfusion if needed. [4]
- Consider neutropenic colitis in a patient receiving topotecan who develops fever, neutropenia, and abdominal pain. [4]

*Selected FDA-supported systemic options for persistent, recurrent, or metastatic cervical cancer. [3][4][8]*

| Therapy | Eligible population in supplied source | Dose or regimen | Key efficacy finding | Major selection issue |
| --- | --- | --- | --- | --- |
| Pembrolizumab plus chemotherapy with or without bevacizumab | Persistent, recurrent, or metastatic disease with PD-L1 CPS ≥1. [8] | Pembrolizumab 200 mg plus chemotherapy with or without bevacizumab in the FDA-reviewed trial; continued until progression, unacceptable toxicity, or 24 months. [8] | Median OS not reached versus 16.3 months; HR 0.64. [8] | Requires PD-L1 CPS ≥1 by FDA-approved test. [8] |
| Tisotumab vedotin-tftv | Recurrent or metastatic disease progressing on or after chemotherapy. [3] | 2 mg/kg IV every 3 weeks; maximum 200 mg for patients weighing at least 100 kg. [3] | ORR 24%; median response duration 8.3 months. [3] | Boxed warning for ocular toxicity. [3] |
| Topotecan plus cisplatin | Stage IVB, recurrent, or persistent disease not amenable to curative surgery or radiation. [4] | Topotecan 0.75 mg/m² IV days 1–3 plus cisplatin 50 mg/m² IV day 1, every 21 days. [4] | Median survival 9.4 versus 6.5 months with cisplatin alone. [4] | High myelosuppression burden and renal constraints. [4] |

## Apply emerging evidence cautiously

Not all technically promising tests or prediction tools are ready for clinical adoption.

Urine-based HPV and methylation strategies are promising, especially for reaching underscreened populations, but the cited clinical study was performed in European referral and control cohorts rather than a U.S. population screening program. It explicitly identifies the need for longitudinal validation to define safe screening intervals. [13]

Machine-learning studies using small public datasets should not guide clinical diagnosis or replace validated screening and diagnostic pathways. One cited model achieved near-perfect performance using a dataset of 858 records, but the model incorporated Schiller, Hinselmann, cytology, and biopsy-related testing variables; these are not independent pre-screening risk factors and create a high risk of circular prediction rather than clinically transportable diagnostic performance. [15]

For screening and triage, use patient-important outcomes—not only cross-sectional test accuracy—to assess benefit. The network meta-analysis concludes that comparative strategies need evaluation at the program level, including false-positive procedures, false negatives, long-term outcomes, resources, and costs. [14]
- Do not use AI risk scores as a replacement for HPV testing, cytology, colposcopy, histology, or formal staging. [15]
- Do not adopt urine methylation triage as routine U.S. care solely on referral-cohort performance. [13]
- When interpreting screening evidence, distinguish detection of CIN2+ from prevention of invasive cancer and from treatment benefit. [14]

*Evidence limitations relevant to current U.S. practice. [13][14][15]*

| Evidence type | Potential value | Why it should not yet change routine care |
| --- | --- | --- |
| First-void urine methylation study | May enable molecular triage from a home-collected sample. [13] | Referral-enriched cohort and lack of longitudinal screening validation limit generalizability. [13] |
| Screening network meta-analysis | Quantifies sensitivity-specificity tradeoffs among HPV and cytology strategies. [14] | Heterogeneity and cross-sectional accuracy do not establish a single optimal program for every population. [14] |
| Machine-learning risk model | Illustrates prediction-method development. [15] | Use of diagnostic test variables and a small public dataset limits clinical transportability. [15] |

## Common questions

### What is the most actionable biomarker in recurrent or metastatic cervical cancer?

PD-L1 expression is directly actionable for pembrolizumab plus chemotherapy, with or without bevacizumab, in persistent, recurrent, or metastatic disease when CPS is at least 1 by an FDA-approved test. [8]

### Can a negative HPV result exclude the need for colposcopy in high-grade cytology?

No. FDA HPV-device guidance states that a negative HPV result in women aged 30 years or older with greater than ASC-US cytology should not prevent colposcopy. [1]

### Why is brachytherapy important in locally advanced cervical cancer?

Brachytherapy is described as an essential component of locally advanced cervical cancer treatment and is associated with lower cervical cancer-specific and all-cause mortality in U.S. observational data. [18]

### Is urine-based cervical cancer screening ready for routine U.S. use?

Not based on the supplied evidence. First-void urine HPV and methylation testing is promising, but validation in longitudinal screening populations is still needed before defining routine screening intervals or management pathways. [13]

## References
1. Establishing the Performance Characteristics of In Vitro ... — www.fda.gov — https://www.fda.gov/media/92930/download
2. highlights of prescribing information — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9c6fc66b-522f-499d-961a-cde6ca0ec2e5&type=display
3. FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer | FDA — www.fda.gov — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer
4. These highlights do not include all the information needed to use TOPOTECAN INJECTION safely and effectively.
 
      
See full prescribing information for TOPOTECAN INJECTION.
 
      
      
      
TOPOTECAN Injection
 
      
Must be diluted before intravenous infusion
 
      
Initial U.S. Approval: 1996 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7636bc1e-77b6-46ad-9df0-c8bb1c5e503f&type=display
5. ZETIA — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=
6. See full prescribing information for complete boxed warning. — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9c75e30a-a410-40f1-b653-04d532bd9144
7. OCE Conversations on Cancer, Cervical Cancer Treatment Innovation: A Collaborative Discussion - 01/14/2025 | FDA — www.fda.gov — https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/oce-conversations-cancer-cervical-cancer-treatment-innovation-collaborative-discussion-01142025
8. FDA approves pembrolizumab combination for the first-line treatment of cervical cancer | FDA — www.fda.gov — http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-combination-first-line-treatment-cervical-cancer
9. First Drug Treatment for Late-Stage Cervical Cancer Approved | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/first-drug-treatment-late-stage-cervical-cancer-approved-FW200606160000003
10. Screening for Cervical Cancer — www.acpjournals.org — https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-156-12-201206190-00424
11. Screening for Cervical Cancer: U.S. Preventive Services ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-156-12-201206190-00424
12. The effect of marital status on cervical cancer related prognosis: a propensity score matching study | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-19122-3
13. Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer | Communications Medicine — www.nature.com — https://www.nature.com/articles/s43856-026-01512-x
14. Comparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-021-04201-y
15. Enhanced cervical cancer diagnosis using a novel Bayesian fusion ensemble method with explainable AI | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-026-35334-7
16. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention — go.nature.com — https://go.nature.com/3LFNOSK
17. Practice Bulletin No. 157 : Obstetrics & Gynecology — journals.lww.com — https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000001263~practice-bulletin-no-157-cervical-cancer-screening-and
18. Updated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0360301623081324
19. S3519 A Rare Case of Epigastric Pain Caused by... : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/fulltext/10.14309/01.ajg.0000870716.42865.14~s3519a-rare-case-of-epigastric-pain-caused-by-duodenal
20. Human Papillomavirus DNA Testing for Cervical Cancer ... — academic.oup.com — https://academic.oup.com/jnci/article/92/10/818/2905767
21. Guidelines for the Treatment of Recurrent and Metastatic ... — academic.oup.com — https://academic.oup.com/oncolo/article-abstract/7/4/342/6386720
22. AACC Guidance Document on Cervical Cancer Detection — academic.oup.com — https://academic.oup.com/jalm/article-abstract/8/2/382/7030135
23. Cervical cancer: ESMO Clinical Practice Guidelines for ... — academic.oup.com — https://academic.oup.com/annonc/article/28/suppl_4/iv72/3958154
24. Current treatment options and limitations for cervical cancer - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/B9780443289859000057

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.